new glp 1 agonist for weight loss How GLP-1 medications are transforming diabetes and treatment GLP-1 Agonists for Weight Loss:

However, lean body mass also includes organs, bones, and skin

Pharmacists are well suited to advocate for optimal patient care by recommending appropriate agents on the basis of patient-specific considerations and providing appropriate education to people living with T2D

A previous CB1 receptor blocker, Rimonabant, was approved in Europe in 2006 but was discontinued in 2008 owing to serious psychiatric side effects

2 With the use of GLP-1 receptor agonists becoming increasingly more common, anesthesia professionals need to be aware of these medications and the potential risks they pose to patients receiving anesthesia

material, see support primary care staff in managing adult patients on these medications

Neuropharmacology (2015) 89:30817